You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Vascepa reduces ischemic events in heart attack patients, trial finds

Amarin has announced new data has been presented on Vascepa/Vazkepa (icosapent ethyl) in patients with prior heart attack who are at risk for major adverse cardiovascular events.